ArticleOncoTargets and therapy2022

Anlotinib Hydrochloride and PD-1 Blockade as a Salvage Second-Line Treatment in Patients with Progress of Local Advanced Non-Small Cell Lung Cancer in Half a Year After Standard Treatment.

Chengqi Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.